The result presented here finds an enhanced chemosensitivity to HDAC inhibitors for tumor cell lines with defective JAK3. DUAL kinase and HDAC inhibitors have been developed based on the reasoning that specifically blocking more than one oncogenic pathway simultaneously with a combination of different drugs may be a more effective cancer treatment [98]. The gene discussed is JAK3; the disease is cancer.